Last quarter (Q3 2022), Athira Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Athira Pharma's net income was $-20.74M. See Athira Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 83.60M	$ 55.19M	$ 18.67M	$ 4.70M	$ 5.01M
Operating Income	$ -83.60M	$ -55.19M	$ -18.67M	$ -4.70M	$ -5.01M
Net Non Operating Interest Income Expense	$ 1.76M	$ 334.00K	$ -243.00K	$ -295.00K	$ 76.00K
Other Income Expense	$ -2.00K	$ 334.00K	$ -1.04M	$ -171.00K	$ -164.00K
Pretax Income	$ -81.84M	$ -54.85M	$ -19.95M	$ -5.16M	$ -5.10M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -82.36M	$ -54.85M	$ -19.95M	$ -5.06M	$ -5.10M
Basic EPS	$ -2.11	$ -1.49	$ -1.67	$ -0.82	$ -0.82
Diluted EPS	$ -2.11	$ -1.49	$ -1.67	$ -0.82	$ -0.82
Basic Average Shares	$ 157.82M	$ 36.92M	$ 11.97M	$ 6.19M	$ 6.19M
Diluted Average Shares	$ 157.82M	$ 36.92M	$ 11.97M	$ 6.19M	$ 6.19M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 83.60M	$ 55.19M	$ 18.67M	$ 4.70M	$ 5.01M
Net Income From Continuing And Discontinued Operation	$ -81.84M	$ -54.85M	$ -19.95M	$ -5.16M	$ -5.10M
Normalized Income	$ -81.84M	$ -54.85M	$ -19.38M	$ -5.09M	$ -5.10M
Interest Expense	$ 4.00K	$ 3.00K	$ 367.00K	$ 346.00K	$ 9.00K
EBIT	$ -83.32M	$ -54.85M	$ -19.59M	$ -4.82M	$ -5.09M
EBITDA	$ -82.58M	$ -54.37M	$ -19.59M	$ -4.82M	$ -5.09M

Currency in USD

Athira Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing